SAVR – Medxy AI

TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches

By MedXY 01/22/2026

The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and preventing the progression of cardiac damage stages.

Cardiology news

TAVR vs. SAVR in Younger Low-Risk Patients: 3-Year NOTION-2 Insights Highlight Bicuspid Challenges

By MedXY 01/18/2026

Three-year results from the NOTION-2 trial show comparable clinical outcomes between TAVR and SAVR in younger, low-risk patients. However, higher event rates in the bicuspid subgroup suggest a need for caution and individualized procedural selection in this specific population.

Cardiology news Public Health

Surgical Aortic Valve Replacement Emits Twice the CO2 of TAVR: What This Means for Practice and Policy

By MedXY 11/29/2025

A life cycle assessment found SAVR produces roughly double the carbon footprint of transcatheter aortic valve replacement (TAVR), with postoperative ICU and ward care as the main drivers. Results highlight opportunities to decarbonize cardiac care but do not replace individualized clinical decision-making.

Cardiology news Public Health

Surgical aortic valve replacement produces about twice the carbon footprint of transcatheter approaches: clinical and stewardship implications

By MedXY 11/29/2025

A life cycle assessment found SAVR emits ~620–750 kg CO2e per case—roughly double OR- or cath-lab TAVR (~280–360 kg CO2e). ICU length of stay and postoperative care were the dominant contributors, highlighting targets for low-carbon perioperative pathways and policy-level decision-making.

Cardiology news

Long-Term Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement: A Meta-Analysis of Time-to-Event Data

By MedXY 10/12/2025

This meta-analysis evaluates 5-year outcomes comparing TAVI and SAVR across risk profiles, revealing early advantages with TAVI that level off long-term, with no significant difference at 5 years.

Cardiology Specialties

Three-Year Outcomes of NOTION-2 Trial: Comparing TAVR and SAVR in Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis

By MedXY 09/06/2025

The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.

Cardiology Medical News news Specialties

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

By MedXY 08/31/2025

A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team decisions, and follow‑up priorities.